ZH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ZH is not a good buy right now for an impatient investor. With no proprietary buy signals, neutral-to-weak technicals around the pivot (3.742), a slightly bearish options positioning (OI put/call > 1), and deteriorating top-line growth in 2025/Q3, the risk/reward doesn’t favor immediate upside follow-through. I would avoid new buys here; if already holding, I’d lean to selling/rotating out unless price quickly reclaims and holds above ~3.90 (R1) with improving momentum.
Price is slightly below the pivot (3.742) near 3.71–3.77, indicating an indecisive/flat-to-soft near-term posture. MACD histogram is above 0 (0.00725) but positively contracting, which typically signals weakening bullish momentum rather than a fresh uptrend. RSI(6) ~52.6 is neutral (no oversold bounce setup). Moving averages are converging, consistent with consolidation rather than a clear trend. Key levels: support S1 3.586 then S2 3.489; resistance R1 3.899 then R2 3.996. Given post-market weakness (-1.51%), downside tests of support are plausible if it can’t reclaim the pivot quickly. Pattern-based projection also skews weak beyond the very short term (next month expectation -2.2%).
and holds, a technical squeeze toward ~4.00 (R
becomes more plausible.
No near-term news catalysts to spark momentum. 2025/Q3 revenue declined sharply (-22.02% YoY), and gross margin fell (61.26%, -4.16% YoY), pointing to weakening demand/monetization and profitability pressure. Options open interest leans bearish (put/call 1.12). Near-term technicals are not strong: MACD momentum is fading and price is below the pivot, with nearby supports at 3.586/3.489 that could be tested if selling continues.
Latest quarter: 2025/Q3. Revenue fell to 658,929,000 (-22.02% YoY), indicating meaningful top-line contraction. Net income improved to -46,655,000 (up 344.71% YoY) and EPS improved to -0.19 (up 375% YoY), suggesting cost controls reduced losses, but profitability remains negative. Gross margin decreased to 61.26% (-4.16% YoY), a negative quality-of-earnings signal alongside the revenue drop.
No analyst rating/price target change data was provided, so a Wall Street consensus trend cannot be confirmed from this dataset. With the available information, the ‘pro’ case would be loss narrowing and potential technical rebound above ~3.90; the ‘con’ case is the steep revenue decline and margin compression, which typically weighs on sustained upside.
